The FDA recently approved a pretzel-shaped implant that helps some bladder cancer patients keep their bladder. Dr. Chris ...

Bladder cancer is often treated by removing visible tumors and using a type of immunotherapy called BCG, delivered through a ...

Imagine a targeted approach to bladder cancer that spares healthy cells while delivering chemotherapy directly to cancerous ones, offering hope for patients with advanced stages of the disease.

ADVANCED-2 (NCT05951179) is a Phase 2 open-label trial assessing intravesical TARA-002 in NMIBC patients with carcinoma in situ or CIS (± Ta/T1) who are Bacillus Calmette-Guérin (BCG)-Unresponsive ...

The findings showed that disease progression not only worsens patient outcomes but also significantly increases overall healthcare costs. Late-stage disease and post-recurrence cystectomy were ...

The TAR‑200 slow‑release bladder implant cleared tumours in 82% of patients with high‑risk non‑muscle‑invasive bladder cancer ...

BBC apologizes to Trump over editing blunder, rejects defamation claim Scientists Studied 'SuperAgers' For 25 Years And Found ...

Breast cancer advancements include targeted therapies, oral medications for ER-positive/HER2-negative populations, and ...

Growth hormone receptor (GHR) signaling in bladder cancer is associated with advanced tumor stages and poor survival outcomes. High GHR expression in tumors up-regulates genes involved in drug ...

Researchers say a new drug-delivery implant could help patients with hard-to-treat bladder cancer avoid losing their bladders — and stay cancer-free for years.

The trial showed that 63% of patients achieved a complete response (CR) at any time after receiving detalimogene coraplasmid.